Oxcia publishes annual report for 2025
The annual report is available on the website and the CEO comments on the first collaboration agreement as well as ODD from two supervisory authorities.
See the latest news and media coverage for Oxcia. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company targeting DNA damage repair and oxidative stress
oxcia.comLast updated
In short: Oxcia advanced its clinical programs, expanded its advisory board for lung fibrosis, and secured a new patent for its OXC-201 candidate.
The annual report is available on the website and the CEO comments on the first collaboration agreement as well as ODD from two supervisory authorities.
The meeting will consider authorization for issuance of shares, warrants, and convertibles.
Patent already approved in US, Japan, China; pending in Europe, valid until March 2039
Operating result amounted to -8.9 MSEK and OXC-101 showed complete remission in AML patient.
Article ‘Count’ and ‘Share’ for Oxcia AB based on listed parameters only. According to the parameters selected above, there are no articles from Oxcia AB...
Track Oxcia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Oxcia and other trending companies.